In preliminary data that will be submitted in a separate report, we have explored how tumor size can substantially influence the outcome of both A20 and B78 tumors to this same CpG+OX40 in situ vaccine regimen, as well as potential mechanisms underlying these size-dependent differences in response. This evidence concerns the gene TNFRSF4 and neoplasm.